PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Endocyte Announces Presentations at the American Chemical Society (ACS) National Meeting & Exposition
WEST LAFAYETTE, Ind. , Aug. 17, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that two posters will be presented by Endocyte scientists at the ACS National Meeting & Exposition
View HTML
Toggle Summary Endocyte to Present at the 2018 Wedbush PacGrow Healthcare Conference
WEST LAFAYETTE, Ind. , Aug. 08, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that the company’s management team will present at the 2018 Wedbush PacGrow Healthcare Conference on
View HTML
Toggle Summary Endocyte Provides Second Quarter 2018 Financial Results and Operational Update
                       -Initiated phase 3 VISION study of 177 Lu-PSMA-617 in mCRPC-                  -Secured commercial supply of no-carrier-added Lutetium-177 through 2035 - -Investigational new drug (IND) filing for EC17/CAR T-cell therapy on track for fourth quarter 2018 -           
View HTML
Toggle Summary Endocyte Announces Second Quarter 2018 Financial Results and Operational Update Call
WEST LAFAYETTE, Ind. , July 25, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that the company will host a conference call on Tuesday, July 31st , at 8:30 a.m.
View HTML
Toggle Summary Endocyte and ITM Announce Long-Term Supply Agreement for No-Carrier-Added Lutetium-177
Strategic Partnership Supports Commercialization Beyond Ongoing Phase 3 VISION Trial of 177Lu-PSMA-617 WEST LAFAYETTE, Ind. and GARCHING, Germany, July 09, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), and ITM Isotopen Technologien München AG (ITM), a specialized radiopharmaceutical group
View HTML
Toggle Summary Image Following Treatment with 177Lu-PSMA-617 Selected by Society of Nuclear Medicine and Molecular Imaging as Image of the Year
Image depicts PSMA PET scans of eight patients with exceptional responses from investigator-sponsored Phase 2 study WEST LAFAYETTE, Ind., June 26, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment,
View HTML
Toggle Summary Endocyte to Join the Russell 3000® Index
WEST LAFAYETTE, Ind. , June 25, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that its common stock has been selected for inclusion in the broad-market Russell 3000 ® Index
View HTML
Toggle Summary Endocyte Announces Presentations on PSMA-617 at the 2018 Society of Nuclear Medicine and Molecular Imaging Annual Meeting
Presentations highlight Endocyte’s alpha and beta-emitting radioligand therapies WEST LAFAYETTE, Ind. , June 22, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that multiple
View HTML
Toggle Summary Endocyte Announces Enrollment of First Patient in Phase 3 VISION Trial of 177Lu-PSMA-617 in Prostate Cancer
Additional data from phase 2 investigator-initiated trial of 177Lu-PSMA-617 presented at American Society of Clinical Oncology (ASCO) WEST LAFAYETTE, Ind. , June 05, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized
View HTML
Toggle Summary Endocyte to Present at Jefferies Healthcare Conference
WEST LAFAYETTE, Ind. , May 29, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that the company’s management team will present at the Jefferies Healthcare Conference on Tuesday,
View HTML